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ABSTRACT
A low dose step-up and step-down regimen for induction of ovu-
lation using urinary FSH was compared in a prospective randomized
fashion in 37 normogonadotropic clomiphene-resistant oligo- or
amenorrheic infertile women. The objectives was to assess potential
differences in duration of treatment, ovarian stimulation (serum FSH
levels), and response [serum estradiol (E2) levels and number and size
of follicles]. Monitoring (blood sampling and transvaginal sonogra-
phy) took place on the day of initiation of treatment, the first day of
ovarian response as assessed by ultrasound (i.e. the first day a follicle
$10 mm could be recognized), the day of hCG administration to
induce ovulation, and 3 days thereafter.
The median duration of treatment in the low dose step-up group
was 18 (range, 7–41) days compared to 9 (range, 4–16) days in the
step-down group (P 5 0.003), and the total numbers of ampules
administered were 20 (range, 7–69) and 14 (range, 7–33), respectively
(P 5 NS). Serum FSH levels from the first day of sonographic ovarian
response until the administration of hCG were constant (median
increase, 2%/day) in patients receiving the low dose step-up protocol,
but showed a decrease (median, 5%/day) in step-down cycles (P ,
0.001). Monofollicular growth, defined as not more than one follicle 16
mm or larger on the day of hCG administration, was observed in 56%
of low dose step-up and 88% of step-down cycles (P 5 0.04). The
percentage of patients with normal range periovulatory E2 serum
levels (500–1500 pmol/L) was 33% in the low dose step-up group vs.
71% in the step-down group (P 5 0.03).
We conclude that a step-down protocol for gonadotropin induction
of ovulation exhibits a more physiological, late follicular phase FSH
serum profile than a low dose step-up protocol. This results in a
shorter duration of treatment, a greater number of monofollicular
cycles, and more cycles with periovulatory E2 levels within the normal
range in the step-down protocol. (J Clin Endocrinol Metab 82: 3597–
3602, 1997)
SINCE THE early 1960s, infertile patients with anovula-tion have been treated with human menopausal go-
nadotropin and hCG. This treatment modality has proven to
be effective (1), although associated complications (princi-
pally multiple pregnancies and ovarian hyperstimulation)
remain an issue of major concern (2–5). Based on Brown’s
theory (6), conventional step-up regimens have been mod-
ified to a low dose step-up protocol (7, 8). A lower initial dose
of a half-ampule or one ampule per day is used, and the dose
is increased by small increments (half-ampule per day) at 1-
to 2-week intervals in an attempt to slowly and prudently
surpass the individual FSH threshold. In both treatment reg-
imens the administered dose of gonadotropins is kept con-
stant from the day of sufficient ovarian response on ultra-
sound (4, 7, 8) until the day of hCG administration to induce
ovulation. The risk of multiple follicle development and sub-
sequent complications is reduced with low dose step-up as
compared to conventional step-up regimens (7, 8). However,
low dose step-up regimens may also lead to multiple follicle
development (9) and appear to be more time consuming (10).
Due to the long half-life of FSH (11, 12), fixed daily doses of
gonadotropin preparations may result in accumulation and,
therefore, increased FSH serum levels in the late follicular
phase. It has been reported that the magnitude of FSH ac-
cumulation determines ovarian hyperresponse in patients
treated with in vitro fertilization (13).
In contrast, during the normal menstrual cycle the dom-
inant follicle continues to grow despite decreasing FSH se-
rum levels (14–16). Diminishing concentrations of FSH dur-
ing the follicular phase have been shown to be essential for
monofollicle development in the monkey model (17) as well
as in the human (18). It is possible that elevated late follicular
phase FSH levels during step-up regimens unintentionally
interfere with single dominant follicle selection (19). Our
previous studies have shown that a step-down gonadotropin
dose regimen more closely resembles decreasing FSH levels
found in spontaneous cycles (16, 20, 21) and can serve as a
safe and successful treatment alternative for women suffer-
ing from clomiphene-resistant anovulation (22). This study is
the first prospective randomized comparison between a low
dose step-up and a step-down protocol for gonadotropin
induction of ovulation. The objective was to assess potential
Received February 12, 1997. Revision received July 22, 1997. Accepted
July 24, 1997.
Address all correspondence and requests for reprints to: Bart C. J. M.
Fauser, M.D., Ph.D., Division of Reproductive Medicine, Depart-
ment of Obstetrics and Gynecology, Dijkzigt Academic Hospital,
Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
* This work was supported by Stichting Voortplantingsgeneeskunde
Rotterdam.
0021-972X/97/$03.00/0 Vol. 82, No. 11
Journal of Clinical Endocrinology and Metabolism Printed in U.S.A.
Copyright © 1997 by The Endocrine Society
3597
 at Medical Library Erasmus MC on December 13, 2006 jcem.endojournals.orgDownloaded from 
differences in treatment duration and dose, ovarian stimu-
lation, and response.
Subjects and Methods
Subjects
Inclusion criteria were infertility (seeking pregnancy $1 yr), cycle
abnormalities [oligmenorrhea (interval between menstrual bleedings
.35 days) or amenorrhea (no bleeding for at least 6 months)], FSH serum
concentration within the normal range (1–10 IU/L), clomiphene resis-
tance (defined as failure to ovulate or conceive after clomiphene treat-
ment up to a daily dose of 150 mg from cycle days 3–7 during at least
three consecutive cycles), age 20–40 yr, normal PRL (,15 nmol/L) and
TSH (0.2 mIU/L , TSH , 4.2 mIU/L) serum levels, absence of evidence
of bilateral tubal occlusion as assessed by hysterosalpingogram,
and absence of severe oligospermia (sperm count ,10 3 106
spermatozoa/mL).
Thirty-seven patients attending our Fertility Clinic fulfilling the
above criteria were included in this study. Patients included (see Table
1) had a median age of 29 yr (range, 20–40 yr), a median body mass index
(weight divided by height squared) of 25 kg/m2 (range, 18–41 kg/m2),
and a median duration of infertility of 3 yr (range, 2–7 yr). The protocol
was approved by the local human subject committee, and informed
consent was obtained from all participants.
Study design
This was a prospective, randomized, single center study comparing
a low dose step-up with a step-down dose regimen for induction of
ovulation with urinary FSH. Initial screening was performed within 2
months before inclusion. Initial screening included random blood with-
drawal and transvaginal sonography (TVS). Sonographic monitoring
was performed by a single observer (E.J.P.v.S.), using an ultrasound
machine (model EUB-415, Hitachi Medical Corp., Tokyo, Japan) with a
6.5-MHz transvaginal transducer. The ovaries were localized in relation
to the iliac vessels. Follicles appeared as round or ovoid translucent
structures 2 mm or more in diameter. Follicle number was established
by scanning each ovary from the inner to the outer margin in longitu-
dinal cross-section. The ovarian volume was estimated according to the
following formula: 1⁄2 (A 3 B 3 C), where A is the longitudinal diameter,
B is the antero-posterior diameter, and C is the transverse diameter of
the ovary. Mean follicle number and mean ovarian volume were cal-
culated from the sum of the left and right values divided by 2. Ovarian
stroma echogenicity was scored as 1 (normal), 2 (moderately increased),
and 3 (markedly increased) as described by Pache et al. (23). Total stroma
count was the combined stroma scores of left and right ovaries. For each
patient, blood samples for initial screening were randomly taken
through venipuncture, centrifuged within 2 h after withdrawal, and
stored at 220 C until assayed. Before entering the protocol, serum from
each patient was assayed for immunoreactive FSH, LH (normal range,
1.3–6.9 IU/L) (24), estradiol (E2), testosterone, androstenedione, sex
hormone-binding globulin, and progesterone as previously described
(25). After inclusion, patients were randomized by receiving a study
number corresponding to a sealed envelope containing the protocol to
be followed.
Gonadotropin treatment was started 3–5 days after the initiation of
spontaneous or progestagen-induced withdrawal bleeding. Patients re-
ceived daily im injections of purified urinary FSH (Follegon, Organon,
Oss, The Netherlands) from a single batch (no. 74029003). Monitoring of
ovarian response by TVS was performed every 2 or 3 days until hCG
(Pregnyl, Organon) was administered. hCG was injected im as a single
dose of 10,000 IU on the day upon which at least one follicle 18 mm or
larger was observed by TVS examination. If more than three follicles 16
mm or larger were present, stimulation was canceled, and the patient
was advised to use barrier contraceptives. During the study, blood
samples were obtained on the day treatment was initiated, the day of
sufficient ovarian response, the day of hCG injection, and 3 and 7 days
thereafter. Sufficient ovarian response was defined as visualization of a
follicle 10 mm or larger by TVS, which coincides with the appearance
of the dominant follicle in the normal menstrual cycle (16, 23). FSH
injections were administered between 0800–1200 h. Blood withdrawal
was performed just before gonadotropin injection, i.e. 24 h after the
previous injection. During treatment, the ovarian response was moni-
tored by TVS only.
Low dose step-up protocol
The starting dose of FSH was one ampule (75 IU) per day. The first
increase in dose by a half-ampule per day was based on absence of a
follicle 10 mm or larger after 14 days. The dose was increased by a
half-ampule per day every 7 days if an ovarian response was lacking. If
a sufficient ovarian response was observed, the dose was kept constant
until the administration of hCG. No luteal support was provided.
Step-down protocol
The starting dose of FSH was two ampules (150 IU) per day. The first
decrease in dose by a half-ampule per day was based on visualization
of at least one follicle 10 mm or larger. The initial dose was increased by
a half-ampule per day if the ovarian response remained absent after 5
days. If follicular growth remained absent over the following 10 days
(two incremental steps of a half-ampule per day), further medication
was withheld, and the cycle was canceled. A further dose decrease, each
time by a half-ampule per day, was performed every 3 days to a min-
imum dose of one ampule per day if follicular growth continued. This
dose was sustained until the day hCG could be administered. No luteal
support was provided.
Data analysis
Before initiation of the study, power calculations were performed to
determine the required number of patients for the detection of differ-
ences in serum FSH and E2 levels and the number of dominant follicles
on the day of hCG administration, comparing both dose regimens. Based
on the literature and our previous studies (20, 21), differences were
estimated to be 30%. This difference was calculated to be apparent with
at least 12 patients in each group.
Values given are the mean 6 sd unless stated otherwise. The P values
given are two-sided, and 0.05 was considered the limit of statistical
significance. Differences between patient groups were tested using the
Mann-Whitney test, Student’s t test, or Fisher’s exact test. The distri-
bution of ovarian follicles was arbitrarily classified in categories accord-
ing to size (10–12, 12–16, and $16 mm), as described previously (22).
Ovulation after hCG administration was determined by the collapse of
TABLE 1. Initial patient characteristics (median and range) of 37
normogonadotropic clomiphene-resistant oligo- or amenorrheic
infertile women treated with urinary FSH for ovulation induction
Low dose step-up Step-down
n 19 18
Age (yr) 28 (20–35) 30 (23–40)
BMI (kg/m2) 26 (19–40) 25 (18–41)
Infertility duration (yr) 3 (2–5) 3 (2–7)
Amenorrhea (%) 26 33
Primary infertility (%)a 63 61
Serum hormone concentrationsb
LH (IU/L) 5.6 (1.5–15.4) 5.8 (2.7–13.8)
FSH (IU/L) 4.9 (2.7–9.0) 4.5 (2.2–6.8)
E2 (pmol/L) 238 (97–378) 250 (75–864)
T (nmol/L) 2.1 (1.3–4.6) 2.2 (1.4–4.3)
AD (nmol/L) 15.4 (8.5–30.4) 13.3 (9.3–32.8)
SHBG (nmol/L) 32 (10–128) 47 (20–164)
Transvaginal ultrasonography
Mean ovarian vol (mL) 8.5 (4.0–14.9) 11.3 (5.7–18.4)
Mean follicle no./ovary 12.5 (1.5–15.0) 14.3 (5.5–15.0)
Total stroma countc 4 (2–6) 4 (2–5)
Patients were randomized for low dose step-up or step-down dose
regimens.
a Absence of previous pregnancies in the present relationship.
b Blood samples were taken at random within 1 month preceding
the study cycle.
c Scored on a scale from 1 (normal) to 3 (severely increased density)
and added for both ovaries.
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the dominant follicle on TVS and midluteal P levels. Pregnancy diag-
nosis was confirmed by a positive urinary pregnancy test (hCG, .25
IU/L), and ongoing pregnancy was confirmed by sonographic evidence
of an intrauterine gestational sac and fetal heart beat. Patients attending
our clinic within 2 weeks after the last administration of gonadotropins
with serious abdominal discomfort, sonographic evidence of grossly
enlarged ovaries, and increased quantities of free abdominal fluid were
reported to be suffering from ovarian hyperstimulation syndrome.
Results
Thirty-seven normogonadotropic patients with clomi-
phene-resistant anovulation entered the study protocol. Af-
ter randomization, 19 (51%) patients received exogenous
FSH treatment according to a low dose step-up regimen, and
18 patients received a step-down dose regimen. Patient char-
acteristics of both groups are shown in Table 1. The groups
did not differ in any of the characteristics shown.
In both groups one patient dropped out early due to ex-
tensive vaginal bleeding during gonadotropin treatment.
Cancellation due to ovarian hyperresponse (more than three
follicles $16 mm on the day of hCG administration) did
occur once in the low dose step-up regimen. Seventeen pa-
tients in both groups received hCG. One patient in each
group presented with low luteal progesterone levels (,10
nmol/L), suggesting the absence of ovulation.
Clinical treatment outcome is presented in Table 2. The
median first day of ovarian response monitored by TVS in the
low dose step-up group was treatment day 11 (range, 5–33)
vs. day 5 (range, 3–13) in the step-down group (P , 0.001).
The median day of administration of hCG in the low dose
step-up group was 20 (range, 8–42) vs. 10 (range, 5–17) in the
step-down group (P 5 0.001). In the low dose step-up group,
7 patients (39%) acheived a preovulatory follicle using not
more than 1 ampule of urinary FSH/day. In the step-down
group, the initial dose of two ampules per day was sufficient
to induce an ovarian response within 5 days in 14 (78%)
patients.
Median serum FSH levels on the day treatment was started
did not differ in the two groups and were higher on the first
day of ovarian response, as determined by ultrasound, in the
step-down group [6.3 IU/L (range, 4.7–10.2 IU/L) vs. 5.4
IU/L (range, 3.4–9.5 IU/L); P 5 0.04; see Fig. 1]. From the day
of ovarian response until the day of hCG administration, FSH
levels showed an increase in 11 (61%) cycles in the low dose
step-up group, whereas in the step-down group, FSH levels
showed a decrease in all cycles (P , 0.001). The low dose
step-up group exhibited a median increase in serum FSH
during the late follicular phase of 0.6 IU/Lzday (range, 2.0 to
24.3 IU/Lzday; 2% increase/day), whereas in the step-down
group, FSH levels decreased during the same period (1.3
IU/Lzday; range, 0.2–5.0 IU/Lzday; 5% decrease/day; see
Fig. 1). Differences between the groups in changes in serum
FSH during the late follicular phase were highly significant
(P , 0.001). Patients treated according to the low dose
step-up protocol with decreasing late follicular serum FSH
levels exhibited monofollicle growth in five (71%) cases,
whereas in the group with increasing serum FSH levels, there
were five (45%) patients with monofollicular growth (P 5
NS.). No significant correlation was observed between ab-
solute individual changes in serum FSH concentrations in the
late follicular phase (between the day of ovarian response
and the day of hCG administration) and serum E2 levels or
number of follicles ($12 mm diameter) on the day of hCG
administration in the total study group or in both subgroups
separately (Fig. 2).
The distribution of follicles (arbitrarily classified in size
categories of 12–16 and $16 mm diameter) on the day of hCG
administration is shown in Fig. 3. Medium-sized follicles of
10–16 mm were absent in 22% and 29% of low dose step-up
and step-down cycles, respectively (P 5 NS). Ovarian vol-
umes on the day of hCG administration and 3 days thereafter
showed no differences between the groups (data not shown).
The median increase in serum E2 levels from the day of
ovarian response until the day of hCG administration was
179 pmol/Lzday (range, 33–742 pmol/Lzday) in the low dose
step-up group and 250 pmol/Lzday (range, 23–1273 pmol/
Lzday) in the step-down group (P 5 NS).
In the step-up group, one pregnancy ended in an early
miscarriage at 6 weeks, and one appeared to be a tubal
pregnancy and had to be removed by laparoscopy. The on-
going pregnancy rate was 13% in the step-up group and 31%
in the step-down group.
Discussion
Knowledge regarding the interplay between serum FSH
levels and follicle growth during the normal menstrual cycle
TABLE 2. Clinical outcome of 35 normogonadotropic clomiphene-resistant oligo- or amenorrheic infertile women treated with urinary
FSH for ovulation induction
Low dose step-up Step-down P
Median duration of treatment (days) 18 (7–41) 9 (4–16) 0.003
Median no. of ampoules used per cycle 20 (7–69) 14 (7–33) NS
Daily FSH change (IU/L) from the day of ovarian response until hCG, (%/day) 10.6 (12) 21.3 (25) ,0.001
Patients with decreasing late follicular phase FSH levels, no. (%) 6 (39) 17 (100) ,0.001
Monofollicle growth,a no. (%) 10 (56) 15 (88) 0.04
Patients with E2 within normal preovulatory range (500–1500 pmol/L), no. (%) 6 (33) 12 (71) 0.03
Cycles cancelled (no.) 2 1
Overall ovulation rate (%) 84 89
Ongoing pregnancies (no.) 2 5
Multiple pregnancies (no.) 0 0
Abortion (no.) 1 0
Tubal pregnancy (no.) 1 0
Ovarian hyperstimulation (no.) 0 0
Patients were randomized for low dose step-up (n 5 18) or step-down (n 5 17) dose regimens.
a Defined as 1 follicle 16 mm or larger on the day of hCG administration.
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has increased, and the process of selection of a single dom-
inant follicle has been recognized to be dependent on de-
creasing FSH concentrations during the late follicular phase
(17, 18). In contrast, increasing serum FSH levels in the late
follicular phase have been described during conventional
step-up regimens for induction of ovulation, even using a
low dose step-up regimen (26). Step-up regimens ignore the
concept that the FSH threshold should be surpassed for a
limited period of time only (a narrow window) sufficient to
allow a single follicle to gain dominance (6, 10). As compli-
cations of gonadotropin induction of ovulation, such as ovar-
ian hyperstimulation and multiple pregnancy, are related to
multiple follicle development (27), it may be worthwhile to
focus on various dose regimens and resulting patterns in
serum FSH levels. In some ovulation induction studies (26),
late follicular steady state FSH levels were observed during
low dose step-up regimens. Moreover, preliminary data sug-
gest that decreasing serum FSH levels may occur due to
negative estrogen feedback action in some patients (28) or iv
low dose step-up FSH administration (29).
Our group has focused on a method of obtaining serum
FSH levels during gonadotropin induction of ovulation that
more closely mimic physiology (19). These studies have
shown that the late follicular phase FSH profile during a
step-down dose regimen with initial doses of two ampules
per day and decreasing steps of a half-ampule per day closely
resembles serum FSH levels of the spontaneous cycle (20, 21),
and that treatment outcome is at least comparable to that
using low dose step-up protocols (22). To substantiate po-
tential differences, we compared the step-down induction
regimen with a low dose step-up protocol in a prospective
randomized trial. The results obtained indicate that in the
step-down group, serum FSH levels decrease in the late
follicular phase in all patients (median, 5%/day), whereas in
the low dose step-up group, individual serum FSH levels
decrease in only 39% of patients (P , 0.001). The small
number of patients (39%) in the low dose step-up group that
present with decreasing late follicular phase FSH levels con-
sists of patients that in the majority of cases (71%) exhibit
monofollicle growth; the “good responders.” Consistent
with pharmacokinetic studies (11, 12), the overall median
serum FSH concentration in the low dose step-up group
remains fairly stable in the late follicular phase. Another
study in which exogenous FSH was replaced by pulsatile
administration of GnRH when dominant follicle growth was
first recognized showed that multiple follicle growth was
minimized, and a low multiple pregnancy rate could be
obtained (30). The decrease in serum FSH during step-down
ovulation induction in a protocol that combined exogenous
gonadotropins with GnRH agonists showed a more pro-
nounced median decrease of 10%/day (20) compared to the
5% daily decrease demonstrated in the present study. In a
study in which patients were treated according to a low dose
step-up protocol using iv gonadotropin administration with
and without pituitary down-regulation by GnRH agonists
(29), the effect was reversed; in the group treated with GnRH
agonists, serum FSH levels were stable, whereas a minimal
decrease occurred in the group treated with gonadotropins
alone. This may be related to the changes in endogenous FSH
production in nonsuppressed patients. All of the above-
mentioned observations favor a limited role for E2 in late
follicular FSH patterns in gonadotropin-stimulated cycles.
We observed more monofollicle cycles (88% vs. 56%) and
more preovulatory serum E2 levels in the physiological range
(71% vs. 33%) in the step-down group than in the low dose
step-up group. This may coincide with reduced chances for
multiple pregnancy and ovarian hyperstimulation (27, 31).
The reported percentages of monofollicle cycles in low dose
step-up studies vary substantially due to different criteria
used for defining monofollicular growth and cycle cancel-
FIG. 1. Serum FSH (international
units per L) and E2 (picomoles per L)
levels on the day of initiation of ovula-
tion induction with urinary FSH
(Start); the first day of ovarian re-
sponse, defined as the first day a dom-
inant follicle could be recognized using
transvaginal sonography (Response);
the day of hCG administration to induce
ovulation (hCG); and 3 days thereafter
(hCG13) in 35 normogonadotropic
clomiphene-resistant oligomenorrheic
or amenorrheic infertile women. This
group was randomized for a step-down
dose regimen (left panel) or a low dose
step-up regimen (right panel). Only cy-
cles with ongoing follicle growth are in-
cluded. Data are presented as box and
whisker plots, whereas boxes encom-
pass values between the 25th and 75th
percentiles, horizontal lines represent
median values, and “whiskers” give the
95% range of the values. See text for
statistical evaluation.
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lation. The small subgroup of patients in the step-down pro-
tocol with very high late follicular phase serum E2 levels
(patients that hyperstimulate with the starting dose) may
respond better to a lower starting dose of gonadotropins.
Another feature observed in this study is that the step-down
group ovulated after a shorter induction time (9 vs. 18 days).
Using a low dose step-up protocol, patients may initially be
exposed to serum FSH levels below the threshold for an
extended period of time, resulting in a longer treatment
period than strictly necessary. The treatment duration and
number of ampules used in the low dose step-up regimen in
our study are comparable to data reported previously (7, 8).
Few other studies have reported the application of exoge-
nous FSH in a step-down fashion for induction of ovulation
(32, 33). The inclusion criteria used and a rigid step-down
protocol render it difficult to draw conclusions from these
studies. A large randomized study comparing conventional
step-up and step-down regimens (initial dose of three am-
pules per day) has only appeared in abstract form (33).
In conclusion, our findings suggest that in a group of
normogonadotropic clomiphene-resistant anovulatory infer-
tile women, induction of ovulation using a step-down go-
nadotropin dose regimen results in comparable ovulation
and pregnancy rates and a much shorter induction period
than that required with a low dose step-up regimen. This
may bring health economic benefits (more ovulations per
given period of time). In addition, the late follicular phase
serum FSH profile is more physiological and results in more
monofollicular cycles and more cycles in which E2 levels are
within the normal preovulatory range. These observations
may have important implications for the risk of ovarian
hyperstimulation and multiple pregnancy.
FIG. 2. Distribution of individual serum E2 levels (upper panel) and
number of follicles 12 mm or more in diameter (lower panel) on the
day of hCG administration in a group of 35 normogonadotropic
clomiphene-resistant oligomenorrheic or amenorrheic infertile pa-
tients treated after randomization according to a low dose step-up
regimen (l; n 5 18) or a step-down dose regimen (E; n 5 17) for
induction of ovulation with urinary FSH. Significant correlation be-
tween these parameters and late follicular phase (between the day of
ovarian response and the day of hCG administration) changes in
serum FSH concentrations could not be observed in the total study
group or separately in the two subgroups.
FIG. 3. Distribution of number of ovarian follicles (arbitrarily clas-
sified as 12–16 mm in diameter (upper panel) and $16 mm (middle
panel)] and serum E2 levels (lower panel) on the day of hCG admin-
istration in 35 normogonadotropic clomiphene-resistant oligomenor-
rheic or amenorrheic infertile women randomized for a step-down
dose regimen (n 5 17) or a low dose step-up regimen (n 5 18) for
induction of ovulation with urinary FSH. The asterisk indicates the
significant difference (P 5 0.04) in the percentage of patients (56% vs.
88%) presenting with monofollicular cycles (1 follicle $16 mm only),
comparing both treatment schedules. The percentage of patients (33%
vs. 71%) with normal preovulatory serum E2 levels (500–1500 pmol/L)
is also significantly (P 5 0.03) different.
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